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Abstract
Background: The TRPV4 gene encodes a calcium-permeable ion-channel that is widely expressed, responds to
many different stimuli and participates in an extraordinarily wide range of physiologic processes. Autosomal
dominant brachyolmia, spondylometaphyseal dysplasia Kozlowski type (SMDK) and metatropic dysplasia (MD) are
currently considered three distinct skeletal dysplasias with some shared clinical features, including short stature,
platyspondyly, and progressive scoliosis. Recently, TRPV4 mutations have been found in patients diagnosed with
these skeletal phenotypes.
Methods and Results: We critically analysed the clinical and radiographic data on 26 subjects from 21 families, all
of whom had a clinical diagnosis of one of the conditions described above: 15 with MD; 9 with SMDK; and 2 with
brachyolmia. We sequenced TRPV4 and identified 9 different mutations in 22 patients, 4 previously described, and 5
novel. There were 4 mutation-negative cases: one with MD and one with SMDK, both displaying atypical clinical
and radiographic features for these diagnoses; and two with brachyolmia, who had isolated spine changes and no
metaphyseal involvement.
Conclusions: Our data suggest the TRPV4 skeletal dysplasias represent a continuum of severity with areas of
phenotypic overlap, even within the same family. We propose that AD brachyolmia lies at the mildest end of this
spectrum and, since all cases described with this diagnosis and TRPV4 mutations display metaphyseal changes, we
suggest that it is not a distinct entity but represents the mildest phenotypic expression of SMDK.
Keywords: TRPV4, Metatropic Dysplasia (MD), Autosomal Dominant Brachyolmia (ADBO), Spondilometaphyseal Dys-
plasia Kozlowski Type (SMDK)
Background
Metatropic Dysplasia (MD, OMIM 156530) is a severe
bone dysplasia, observable in the perinatal period, first
described by Maroteaux et al in 1966. Derived from
ancient Greek μετa meaning “with” and τrοπh meaning
“change"; the name refers to the main clinical feature of
the condition, which changes from the newborn period,
with long trunk and short limbs, to childhood, when,
due to progressive spinal changes, it becomes a short
trunk dwarfism. The main abnormalities occur in the
vertebral bodies and the metaphyseal portions of the
long bones, and the clinical and radiological diagnostic
features are well described in the literature [1]. Some
authors have suggested genetic variability in MD, with
an autosomal dominant type and a more severe (lethal)
autosomal recessive type,[2] but Camacho et al (2010)
demonstrated TRPV4 mutations in both lethal and
milder types of MD [3].
Spondylometaphyseal Dysplasia Kozlowski Type
(SMDK, OMIM 1842522) was first described by
Kozlowski, Maroteaux and Spranger in 1967 [4] and it
is the best-characterized SMD. It is an autosomal
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and progressive spine deformities. The typical radio-
graphic features are platyspondyly and medially placed
vertebral pedicles in the spine; metaphyseal irregulari-
ties, especially in the proximal femur; abnormal aceta-
bula and delayed carpal bone age [5]. In 2009 Krakow et
al demonstrated that SMDK, like MD, is caused by
mutations in the gene encoding TRPV4 [6].
Brachyolmia was a term coined in 1969 by Maroteaux
for a group of bone dysplasias which displayed short
trunk short stature, with radiological involvement of the
spine and no significant abnormalities of the long bones
[7]. Twenty years later this group was classified into 4
different types: Hobaek, Toledo and Maroteaux, with
autosomal recessive inheritance, and an autosomal
dominant type of brachyolmia (OMIM 113500). The
Toledo type is distinguished by corneal opacities, but it
is otherwise identical to the Hobaek type; Maroteaux
type was subsequently shown to also have epiphyseal
involvement and it is classified in a different group in
the nosology of skeletal disorders published in 2006 [8].
AD brachyolmia always showed slightly different fea-
tures from the recessive types, with a much more severe
involvement of the spine, progressive scoliosis and
abnormalities in the cervical vertebrae too [7]. In 2008
Rock et al demonstrated that AD brachyolmia is caused
by gain of function mutations in the TRPV4 gene [9].
TRPV4 is a cation channel, non-selectively permeable
to calcium, encoded by a gene on chromosome 12. It
is widely expressed and involved in many different
physiological processes through responses to several
different stimuli [10]. The full understanding of all the
functions of this complicated protein is still elusive,
but new data constantly emerge, explaining some of
the features of this channel. The fact that mutations in
the TRPV4 gene cause bone dysplasias is consistent
with the channel being expressed in osteoblasts and
ostoclasts [11] and having an important role in carti-
lage, since it is expressed in the early stages of chon-
drocyte differentiation [12] and modulates SOX9
expression in cell culture [13].
More than 30 different TRPV4 mutations underlying
these three skeletal dysplasias have been reported in the
literature to date, mutational hotspots have been identi-
fied, and some tentative genotype-phenotype correla-
tions made. We confirm some of the published data and
report 5 new mutations, including the first duplication/
insertion. Our data also call into question the genotype-
phenotype correlations previously reported.
Materials and methods
The study was approved by the Royal Children’sH o s p i -
tal (Melbourne, Australia) human ethics research
committee (project reference 20045). All patients gave
their informed consent for the study.
Clinical assessment of the patients was done by partici-
pating clinicians; the radiological features were reviewed
by bone dysplasia experts (RS, DS). The key diagnostic
criteria for MD were severe platyspondyly, progressive
spinal deformity, halberd-shaped pelvis and dumbbell-
shaped diaphyses. SMDK was characterized by platysopn-
dyly, overfaced pedicles, flared metaphyses of the long
bones and flat acetabula. AD brachyolmia was consid-
ered, based on the literature [8], as a condition affecting
only the spine, with platyspondyly and vertebral abnorm-
alities, but no metaphyseal changes (Figure 1).
DNA was extracted from whole blood samples with
standard methods, using a PureLink™ Genomic DNA
Mini Kit (Invitrogen). The sixteen exons and flanking
intronic sequences of TRPV4 (NCBI Reference Sequence
NM_021625.4) were PCR amplified from 25 ng of DNA
using previously described primer sequences and condi-
tions (9). PCR products were then treated with ExoSAP-
IT
® (Affymetrix
®) and sequenced with a BigDye Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems)
using the PCR primers. The products were separated on
a 3130 Genetic Analyzer (Applied Biosystems). Each
mutation was confirmed on a second PCR product, and
the parents were tested where possible. If the parents
were not available a panel of 90 control DNAs obtained
with approval from the Australian Red Cross Blood Ser-
vice Ethics Committee was tested.
F o rt h en o v e lm i s s e n s ev a r i a n t sw ea l s oc h e c k e dt h a t
the involved amino acids were conserved among diverse
species on PANTHER (http://www.pantherdb.org) and
performed in silico analysis with SIFT (http://sift.jcvi.
org) and POLYPHEN (http://genetics.bwh.harvard.edu/
pph).
Results
We analysed DNA samples from 26 subjects: 15 had a
diagnosis of MD; 9 had SMKD; and 2 had brachyolmia.
We found mutations in 22 patients from 17 families:
among our patients there are familial cases of both MD
(patients 2 and 3 and patients 5, 6, and 7) and SMDK
(patients 19, 20, and 21). We found 9 mutations: 4 had
been previously described, while 5 were novel (Table 1).
All the mutations, other than c.1566_68dup (p.
L523dup), were missense mutations. The amino acids
involved in new mutations were conserved among spe-
cies on PANTHER (Additional file 1). SIFT and POLY-
PHEN both predicted Y591C, R594H, R594S, P799L,
P799S were deleterious but gave discordant results for
K407E and F617L. The mutation Q239H was not con-
sidered deleterious by either SIFT or POLYPHEN, but
we evaluated the fact that unaffected parents did not
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tional studies are necessary to confirm the pathogenic
role of this variant.
Clinical features of cases not previously described in
the literature are described in Table 2.
Among the patients with MD, all but one (case 23)
had a clear diagnosis of MD and seven of these cases
had been already described in the literature (cases
2,3,4,9,10,11,14) [1]. There were 2 cases (patients 8 and
14) with a very severe/lethal phenotype.
Patient 8 was born at term with normal birth para-
meters, but immediately hospitalized because of skeletal
malformations and respiratory problems. She had very
severe cervical instability and died at 4 1/2 months of
Figure 1 X-rays of some of the cases described.A ,B ,C ,p e l v i s ,l e g sa n dl a t e r a ls p i n eo fc a s e5( M D - S M D Kb r i d g i n gp h e n o t y p e ) ;D ,c a s e8
(MD); E, F, AP spine and pelvis of case 16 (SMDK); G, H, lateral spine and pelvis of patient 18 (SMDK); I, AP spine and pelvis of case 19 (SMDK); J,
AP spine and pelvis of case 20 (SMDK); K, AP spine and pelvis of case 21 (SMDK); L, lateral spine and pelvis of case 26, who had some minor
spinal changes and no metaphyseal involvement.
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respiratory decompensation. The mutation we found in
her (P799S) has already been described as a typical MD
mutation and the codon is a mutational hotspot [14].
In patient 14, already described in the literature, a
diagnosis of probable lethal bone dysplasia was made
in utero, and the pregnancy was interrupted at 23
weeks of gestation: the post mortem examination led
to the diagnosis of MD [1,15]. The TRPV4 mutation
(Q239H) this patient had is novel and neither of the
parents showed the same change. The analysis on
PANTHER showed that the involved amino acid is
conserved.
Amino acid P799 was mutated in 5 families (cases 2
and 3 are father and daughter) and all these patients
had a typical MD phenotype. Also cases 9, 10 and 11
had a typical MD phenotype [1] and they all had
changes to amino acid R594. We found the recurrent
mutation R594H, commonly described in SMDK
patients,[6,14] but also a new change, c.1780C>A (p.
R 5 9 4 S )i ns u b j e c t9 .H eh a sav e r ys e v e r es p i n a lp h e n o -
type for which he underwent several surgeries and
which is the cause, in adulthood, of restrictive lung dis-
ease [1].
Cases 5, 6 and 7 are from the same family (mother
and two sons): initially a diagnosis of MD was made,
but after further reviewing the x-rays, we diagnosed a
bridging phenotype between MD and SMDK given that
some radiographic features in one sibling were more
consistent with MD, whereas the other sibling had radi-
ology most consistent with SMDK. This illustrates the
degree of intrafamilial variability within this spectrum of
disorders.
Case 1 was born at term with normal birth parameters
after an uneventful pregnancy. In the first months of age
she was repeatedly admitted to hospital because of
recurrent respiratory infections: at 3 1/2 months the
diagnosis of recurrent aspirations, in-coordinate swal-
lowing, narrowing of the distal third of the trachea and
tracheobronchomalacia was made; on this occasion an
incidental finding of spinal abnormalities led to a skele-
tal survey which in turn enabled the diagnosis of MD.
The mutation she carried (K407E) was novel. The
mother did not show the same variant and the father’s
sample was not available; however the mutation was not
found in 90 control individuals (180 chromosomes).
PANTHER shows it is a conserved amino acid and SIFT
considers the change “not tolerated”. These findings led
us to consider this a pathogenic variant.
Patients 15 and 16 had a diagnosis of typical SMDK,
so the finding of the R594H mutation did not surprise
us, since it had already been described as a recurrent
mutation in SMDK [6].
In case 17 a diagnosis of SMDK was made when she
was 2 years old: on x-rays she had platysponyly, meta-
physeal flaring of the long bones, short femoral necks
and a small sacrosciatic notch. The molecular analysis
showed the first described insertion/duplication in the
TRPV4 gene: c.1566_68dup (p.L523dup). The parents
were analysed and the variant is de novo.
Patient 18 was born at term to non-consanguineous
healthy parents and had normal birth parameters. His
perinatal history was reported to be unremarkable and
his motor development was normal (walking at 12
months of age). When he was 18 months old his mother
started noticing some bowing of the lower limbs: at 2
years a skeletal survey was done, the x-rays showed
spinal changes and metaphyseal involvement and a diag-
nosis of SMDK was made. The mutation he carries
(c.1851C>A; p.F617L) has been previously described in a
patient with mild MD [3].
Patient 19 was born after an uneventful pregnancy; his
mother, maternal uncle, grandfather and greatgrand-
mother are all affected by short stature with spinal
changes. The x-rays in different family members showed
severe platyspondyly, overfaced pedicles in some family
Table 1 Patients included in the study, clinical diagnosis
and mutations
Patient Family Diagnosis Mutation Exon
1 1 MD c.1219A>G; p.K407E* 7
2 2 MD c.2396C>T; p.P799L 15
3 2 MD c.2396C>T; p.P799L 15
4 3 MD c.2396C>T; p.P799L 15
5 4 MD/SMDK c.1781G>A; p.R594H 11
6 4 MD/SMDK c.1781G>A; p.R594H 11
7 4 MD/SMDK c.1781G>A; p.R594H 11
8 5 MD c.2395C>T; p.P799S 15
9 6 MD c.1780C>A; p.R594S* 11
10 7 MD c.1781G>A; p.R594H 11
11 8 MD c.1781G>A; p.R594H 11
12 9 MD c.2396C>T; p.P799L 15
13 10 MD c.2396C>T; p.P799L 15
14 11 MD c.717G>C; p.Q239H* 5
15 12 SMDK c.1781G>A; p.R594H 11
16 13 SMDK c.1781G>A; p.R594H 11
17 14 SMDK c.1566_68dup; p.L523dup* 9
18 15 SMDK c.1851C>A; p.F617L 12
19 16 Brachyolmia c.1772A>G; p.Y591C* 11
20 16 SMDK c.1772A>G; p.Y591C* 11
21 16 SMDK c.1772A>G; p.Y591C* 11
22 17 SMDK c.1781G>A; p.R594H 11
23 18 MD negative -
24 19 SMDK negative -
25 20 Brachyolmia negative -
26 21 Brachyolmia negative -
* indicates novel mutations not previously described in the literature
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Page 4 of 8Table 2 Clinical and radiographic features of all patients, a part from the ones already described in the literature (1)
PATIENT 1 5 6 7 8 12 13 15 16 17 18 19 20 21 22 23 24 25 26
DIAGNOSIS MD MD MD MD MD MD MD SMDK SMDK SMDK SMDK SMDK SMDK SMDK SMDK MD SMDK ADB ADB
STATURE SHORT + + + + - + + + + - + + - - + + + +/- +
SHORT TRUNK + + + + - + + + + +/- + + +/- +/- + N/A - + +/-
SPINE (KYPHO)SCOLIOSIS + + + + + + + + + +/- - + +/- - + + +/- - -
PLATYSPONDYLY + + + + - + + + + + + + + + + N/A - + +/-
OVERFACED PEDICLES - +/- +/- +/- - - - + + + + + + + + N/A - - -
PELVIS HALBERD SHAPED + - - - + + + - - - - - - - - N/A - - -
METAPHYSEAL
INVOLVMENT
SHORT
FEMORAL NECKS
+ + + + + + + ++++++++N / A +- -
FLARED
METAPHYSES
+ - +/- +/- ++ + + - - +/- - - - - - N/A - - -
RESPIRATORY
PROBLEMS
+ - - - + + + + --------+ / - -- -
MD = Metatropic Dysplasia; SMDK = Spondylometaphyseal Dysplasia Kozlowski type; ADB = Autosomal Dominant Brachyolmia; the feature is considered as present and severe (++); present (+); mildly present (+/-);
absent (-); data not available (N/A)
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8members and some also showed short femoral necks
and coxa vara. Patient 19 was evaluated at 9 years of
age: he then had a very severe kyphoscoliosis and a
diagnosis of AD Brachyolmia was made, since there
were no significant changes in the metaphyses. Four
years later his sister (case 20) and half brother (case 21)
were referred to the same bone dysplasia expert, who
did not know about the kinship at the time he saw the
x-rays, and made a diagnosis of SMDK. In this family
the mutation c.1772A>G (p.Y591C) was found.
Four of the patients included in this study did not
have TRPV4 mutations. Patients 23 and 24 did not have
typical features of MD and SMDK respectively. Case 23
had some features of MD, like short stature, early
scoliosis and a caudal appendage; but also had learning
disabilities, recurrent knee dislocations, very hyperexten-
sible joints and some dysmorphic features, and likely
had a separate (undiagnosed) syndrome. Case 24 showed
short femoral necks and scoliosis as a child, but also
developed joint laxity, dysmorphic features and a short
limb short stature instead of a short trunk short stature.
Although considered atypical for MD, it is possible that
there could be genetic (locus) heterogeneity in this con-
dition with another (possibly pathway linked) gene
responsible. Cases 25 and 26, diagnosed with brachyol-
mia, had only vertebral changes with absolutely no
metaphyseal involvement. (Table 2)
Discussion/Conclusions
We describe the clinical and molecular features of 26
subjects with TRPV4-related bone dysplasias (MD,
SMDK, and brachyolmia). These data highlight that
these chondrodysplasias constitute an allelic “family” in
which there is a spectrum of overlapping severity ran-
ging from lethal MD to mild AD brachyolmia, which we
contend is the mildest phenotypic expression of SMDK,
as all cases have radiographic evidence of metaphyseal
involvement.
We found 9 mutations in 22 patients: 4 are previously
described mutations, 5 are novel.
This study has also identified the first TRPV4 inser-
tion: a de novo c.1566_68dup (p.L523dup) found in
patient 17, who has a typical SMDK phenotype. The
CCT insertion after the second base of codon 523 main-
tains the leucine at codon 523 and inserts an additional
leucine codon (CCG) at this position. The sequence
thereafter remains in-frame.
Two MD patients had a very severe/lethal phenotype:
patient 8, with mutation P799S and patient 14, with
mutation Q239H. Some authors [2] proposed different
inheritance modes for MD, with a lethal, possibly reces-
sive, type of MD, and a dominant “classic” MD. Others,
however,[3] have shown TRPV4 heterozygous mutations
in very severe/lethal MD.
Our data confirm dominant mutations underlie very
severe/lethal MD. This information is crucial for genetic
counselling and recurrence risk assessment as this disor-
der was previously considered a recessive trait with 25%
recurrence risk.
The family with the Y591C mutation (pts 19,20,21)
was particularly illustrative in the fact that the same
bone dysplasia expert made different diagnoses in half
brothers (AD brachyolmia/SMDK respectively), not
knowing they came from the same family. These cases,
and the fact that neither of the patients (24 and 25)
with purely isolated spinal changes showed TRPV4
mutations, prompted us to critically review the AD bra-
chyolmia phenotype. The first cases of brachyolmia with
TRPV4 mutations reported in the literature showed, in
association with the typical vertebral abnormalities, mild
metaphyseal changes in the femoral heads and delayed
bone age [9]. Dai et al. (2010) wrote about “two SMDK
patients who did not show overt metaphyseal changes
and were considered to be of intermediate severity
between SMDK and Brachyolmia” [14]. Kozlowski ques-
tioned the existence of brachyolmia as a separate entity,
saying that all patients with brachyolmia had at least
some mild metaphyseal changes, with shortening of
femoral necks representing the minimal diagnostic
changes, and for that reason had to be considered as
spondylometaphyseal dysplasia patients [16]. Given
these observations and the data from our study, we pro-
pose that “true” brachyolmia, i.e. with changes limited
only to the spine, is the recessive Hobaek type, while
“autosomal dominant brachyolmia” should be consid-
ered as the mildest end of the spectrum of SMDK.
SMDK cases with very mild metaphyseal changes have
been described [17] as have metaphyseal irregularities
(especially in the femurs) in AD brachyolmia [18].
As the molecular data on TRPV4 mutations are
becoming more available, it is feasible to try to find
valid genotype-phenotype correlations as it is increas-
ingly evident that these TRPV4 skeletal dysplasias, have
considerable phenotypic overlap with blurred
boundaries.
Our data confirm that P799 and R594 are the most
commonly mutated codons in the TRPV4 skeletal dys-
plasias; however, as others have reported [14], it is not
always easy to make a definite association between a
specific codon and a specific phenotype. Codon 799 was
mutated in 6 subjects: this was already considered a
mutational hotspot, and different amino acid changes
had been described. All our patients with a mutation in
codon 799 had MD, consistent with the reported experi-
ence [3,14]. Nine subjects had a mutation at codon 594:
R594H is a recurrent mutation and the finding of a dif-
ferent amino acid change (R594S) confirms this codon
as another mutational hotspot. In contrast to the
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as well as in SMDK. We therefore suggest that the
recurrent mutation R594H should be considered when
an apparent bridging phenotype between SMDK and
MD is observed.
For some of the mutations there seems to be a good
genotype-phenotype correlation, based on the cases
described in the literature, like P799L or F617L, which
are associated respectively with classical MD and “mild”
MD/"severe” S M D K .O u rd a t as h o w ,h o w e v e r ,t h a tt h i s
is not true for all the mutations described and it is not
even possible, at present, to find a true association
between a specific protein domain and bone dysplasia
disease severity. Mutations are spread throughout the
protein and mutations causing MD, for example, are
f o u n di nt h ea n k y r i nr e p e a td o m a i na sw e l la si nt h eC -
terminal domain.
Some of the mutations described in the literature have
been tested functionally and found to be gain of func-
tion mutations. We know TRPV4 is a very complex pro-
tein and many authors have demonstrated with in vitro
experiments that different changes at the same codon
can affect the channel response to agonists differently
[19]. In the last year the picture became even more
complex when mutations in the TRPV4 protein were
shown to cause not only the above-mentioned bone dys-
plasias but also neurologic conditions such as congenital
distal Spinal Muscular Atrophy (SMA), scapuloperoneal
SMA and hereditary motor and sensory neuropathy 2C
(also known as Charcot-Marie-Tooth type 2C) [20-22].
Recently, other bone dysplasias have been associated
with TRPV4 mutations too, like spondylo-epiphyseal
dysplasia, Maroteaux type (pseudo-Morquio syndrome
type 2) and parastremmatic dysplasia [23].
F o raf u l lu n d e r s t a n d i n go ft h ep a t h o g e n i cm e c h a n -
isms that lead from mutations in this complex gene to
such a variety of different conditions, more functional
data on the mutant channels is required as well as more
information about how interactions between the TRPV4
channel and other proteins are disrupted in these condi-
tions and how downstream physiological processes are
perturbed.
In conclusion, the data from this study strongly suggest
that: a) the condition previously considered autosomal
recessive, lethal MD represents the severe end of the MD
phenotypic spectrum, as demonstrated by our findings
and by previous data from the literature [3]; b) MD and
SMDK, should be considered part of a TRPV4 bone dys-
plasia spectrum with significant overlapping clinical and
radiographic features, even within families; c) AD bra-
chyolmia is not a separate phenotypic entity and should be
considered as the mildest expression of the SMDK spec-
trum, while AR brachyolmia has different radiographic
features and, probably, a different genetic cause (Figure 2).
Figure 2 Different perspectives in classification of the TRPV4 bone dysplasias. On the top the classification into separate conditions; on
the bottom the idea that lethal MD is the severe end of the MD spectrum; there is a region where the clinical features of MD and SMDK
overlap; and AD brachyolmia is the mild end of the SMDK spectrum.
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Additional file 1: Panther Alignment. Multiple species alignment of the
TRPV4 protein sequence on Panther shows that the amino acids we
found to be mutated are all conserved among species.
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